JL
Jafco Life Science
Venture CapitalModerateJafco Life Science is a venture capital firm specialized in early and late stage venture investments.
Tokyo, JapanFounded 2017
6
Investments
6
Exits
$3.5B
AUM
100.0%
Exit Rate
Get contact info, warm intros & fit scores
Sign up to unlock emails, Signal intro paths, and personalized fit analysis for Jafco Life Science.
Investment Thesis & Strategy
Jafco Life Science invests in both early and late-stage companies across various industries, seeking to support ventures with significant growth potential.
Notable Exits
CompanyTypeYearValue / Acquirer
Abeona TherapeuticsIPO2015—
Kura OncologyIPO2015—
Fate TherapeuticsIPO2013—
Portola PharmaceuticalsIPO2013—
XencorIPO2013—
Seattle GeneticsIPO2001—
Frequently Asked Questions
Jafco Life Science focuses on Series A, Series B, Series C+ stage investments.